Head to Head Survey: Travere Therapeutics (NASDAQ:TVTX) vs. InflaRx (NASDAQ:IFRX)

InflaRx (NASDAQ:IFRX) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.

Institutional & Insider Ownership

42.4% of InflaRx shares are owned by institutional investors. 16.3% of InflaRx shares are owned by company insiders. Comparatively, 4.4% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares InflaRx and Travere Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30,000.00	5,821.12	-$51.63 million	($0.39)	-3.04
Travere Therapeutics	$651.03 million	7.72	-$25.55 million	($1.29)	-40.58

Travere Therapeutics has higher revenue and earnings than InflaRx. Travere Therapeutics is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

InflaRx has a beta of 2.38, suggesting that its stock price is 138% more volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for InflaRx and Travere Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1	2	5	1	2.67
Travere Therapeutics	2	0	11	0	2.69

InflaRx currently has a consensus target price of $7.43, indicating a potential upside of 526.88%. Travere Therapeutics has a consensus target price of $72.55, indicating a potential upside of 38.59%. Given InflaRx’s higher probable upside, research analysts clearly believe InflaRx is more favorable than Travere Therapeutics.

Profitability

This table compares InflaRx and Travere Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-32.04%	-27.33%
Travere Therapeutics	-18.66%	-185.69%	-17.24%

Summary

InflaRx beats Travere Therapeutics on 10 of the 15 factors compared between the two stocks.

About InflaRx

InflaRx N.V. is a biotechnology company that develops therapies for inflammatory and autoimmune diseases. Its research focuses on the complement system, a part of the immune system that can contribute to inflammation and tissue damage. The company’s lead antibody, vilobelimab, targets the complement protein C5a. In 2023, the U.S. Food and Drug Administration granted emergency use authorization for vilobelimab, marketed as Gohibic, for certain hospitalized adults with COVID-19. InflaRx is also investigating the drug in other inflammatory conditions.

About Travere Therapeutics

Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with an emphasis on kidney and metabolic disorders. The company was formerly known as Retrophin and adopted the Travere Therapeutics name in 2020. Its commercial products include FILSPARI (sparsentan), an oral treatment approved in the United States for adults with primary IgA nephropathy at risk of disease progression, and THIOLA EC (tiopronin), used to help prevent cystine kidney stones in people with cystinuria.